tbuckley/cabot-search huggingface dataset:
A new three-dimensional culture system for hepatocytes using reticulated polyurethane
Authors: Y Sato
Journal: Hepatology (1994)

Poly-N-para-vinylbenzyl-lactonamide (PVLA)-coated reticulated polyurethane (PVLA-RPU) has been employed for the long-term maintenance of primary rat hepatocyte cultures. After 3 days of incubation of 2 × 107 hepatocytes/cm3 embedded in PVLA-RPU discs and kept in culture medium, most cells showed typical hepatocyte morphology, with some bile canaliculus-like intercellular spaces among the hepatocytes on examination with scanning and transmission electron microscopy. The cells were attached to the surface of the PVLA-RPU and formed multicellular spheroids in the reticulated pores. The hepatocytes maintained various liver-specific functions such as albumin secretion, ammonium metabolism, urea synthesis and gluconeogenesis, and they were viable. The liver-specific functions could be maintained for more than 1 month when the cells were kept in the rats' peritoneal cavities. This new system may be useful as a bioreactor for an artificial liver. (HEPATOLOGY 1994;19:1023–1028.)
WORK OF THE UNITED STATES PUBLIC HEALTH SERVICE
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antibiotics in endocarditis due to nutritionally deficient streptococci
Authors: D. S. Stein
Journal: JAMA (1989)

<h3>To the Editor.—</h3> Recently, the American Heart Association's Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease<sup>1</sup>gave their recommendations for the treatment of streptococcal endocarditis, including that caused by nutritionally deficient variants. We feel their recommendation of 4 weeks of intravenous penicillin with at least 2 weeks of an aminoglycoside for treatment of endocarditis caused by nutritionally deficient variants deserves comment. Previous studies<sup>2-4</sup>have demonstrated the isolation of penicillin-resistant strains<sup>5</sup>and that minimal inhibitory concentrations to penicillin of 0.12 μg/mL or greater occur in up to one third of the strains tested. In clinical use, the therapy of penicillin and an aminoglycoside for nutritionally deficient streptococcal endocarditis has resulted in persistently positive blood cultures or positivevalue culture in 38% of the cases reviewed,<sup>5</sup>as compared with the 25% failure rate noted in enterococcal endocarditis.<sup>1</sup>Mortality in patients with nutritionally deficient streptococcal endocarditis who received penicillin
American Journal of Medical Sciences, Philadelphia
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of sickle cell crisis with urea in invert sugar. A controlled trial. Cooperative urea trials group
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comments
Authors: H.K. Fierz
Journal: Psychotherapy and Psychosomatics (1975)

Commentaries| February 12 2010 Comments Subject Area: Psychiatry and Psychology H.K. Fierz H.K. Fierz Zürich Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1975) 25 (1-6): 287–293. https://doi.org/10.1159/000286883 Article history Published Online: February 12 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation H.K. Fierz; Comments. Psychother Psychosom 31 December 1975; 25 (1-6): 287–293. https://doi.org/10.1159/000286883 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 1975Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
StatBite States That Require Health Plans to Cover Patient Care Costs in Clinical Trials
Journal: JNCI Journal of the National Cancer Institute (2011)

One of the concerns that keeps cancer patients from enrolling in clinical trials, according to surveys, is the added expense: Some insurance plans in the U.S. do not cover routine patient care costs, such as doctor visits and laboratory tests, once a patient has joined a clinical trial.However, a growing number of states (those shaded on the map) have passed legislation or instituted special agreements requiring health plans to pay these routine medical expenses.
Fatal Hyperkalemia and Hyperchloremic Acidosis
Authors: Donald A. Feinfeld
Journal: JAMA (1978)

SPIRONOLACTONE is used commonly in conditions associated with secondary hyperaldosteronism. Hyperkalemia is a frequent complication of such therapy, particularly in patients with impaired renal function.<sup>1</sup>The one reported case of fatal hyperkalemia associated with spironolactone therapy occurred in a patient with renal failure.<sup>2</sup> This report concerns a patient without noteworthy renal disease in whom fatal hyperkalemia and hyperchloremic acidosis developed during treatment with spironolactone. <h3>Report of a Case</h3> A 64-year-old man with chronic alcoholism was brought to the emergency room at Bronx Municipal Hospital Center after becoming confused and lethargic. He had had two admissions to another hospital for ascites during the previous four months and was being treated with spironolactone (300 mg/day) and hydrochlorothiazide (50 mg/day). During those admissions he had had a serum creatinine level of 1.0 mg/dl, a BUN level of 23 to 30 mg/dl, and creatinine clearance of 119 ml/min. In the emergency room
Reply
Authors: J Delchier
Journal: Gut (1990)

SIR, -The comments of Drs Colombel, Janin, and Torpier are of interest.We agree that the immune processes which may contribute to the mucosal lesion of coeliac disease may be multifactorial.The eosinophil is a major com- ponent of the inflammatory infiltrate in coeliac disease, although this is frequently not emphasised in descriptions of the lesion.We have recently produced additional evidence that eosinophils and polymorphs are present in increased numbers in the coeliac mucosa: using monoclonal antibodies to Fc receptors (for the gamma chain of IgG) types II and III, which are found on eosinophils and polymorphs, a marked increase in reactive cells was found.The evidence of Dr Colombel and colleagues that many of these eosinophils have degranulated and the associated finding of increased release of granule components points to mech- anisms whereby eosinophils might mediate damage.The possibility that IgA, produced in large quantities in the damaged intestine, may be involved in eosinophil degranulation through interaction with IgA Fc receptors should also be considered.The finding that many coeliac patients react rapidly to gluten challenge (both symptomatically and histologically) is in keeping with more immediate mechanisms of damage also participating in the development of the lesion.Eosinophils are good candidates for such a mechanism.
Hazardous Solid Waste from Metallurgical Industries
Authors: Richard P. Leonard
Journal: Environmental Health Perspectives (1978)

Types of land disposed residuals from selected metal smelting and refining industries are described, as are the origin and disposition of land disposed residuals from the primary copper industry as an example. Quantities of land-disposed or stored residuals, including slags, sludges, and dusts, are given per unit of metal production for most primary and secondary metal smelting and refining industries. Assessments of the hazard potential of residuals are given. Present treatment and disposal of residuals are discussed and assessed for health and environmental protection. Possible technologies for protection of ground and surface water contamination are presented. These include lined lagoons, chemical fixation of sludge, and ground sealing. Possibilities of resource recovery from residuals are discussed. Data are presented showing attenuation of heavy metal ions and fluorides in selected soils. The leachability and mobility of smelting and refining residuals constituents, including heavy metals and fluorides, and other potential toxicants in specific soil, geologic, and hydrologic disposal environments must be carefully considered in setting disposal requirements.
Neuroanatomy
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prognostic Disclosure
Authors: David Grossman
Journal: Annals of Internal Medicine (2002)

Letters3 September 2002Prognostic DisclosureDavid Grossman, MDDavid Grossman, MDThe Cancer Center of Chester County; West Chester, PA 19380Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-5_Part_1-200209030-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In response to the article by Lamont and Christakis (1), I would like to add another confounding problem. Their study was designed to determine whether physician behavior could contribute to the disparity between patients' and physicians' expectations about outcomes of treatment. I cannot agree enough that incorrect information transmitted from physician to patient will have a negative impact on the concordance between physicians' expectations of outcome, patients' expectations of outcome, and the reality of data-based outcome. However, even honest and accurate information delivered by physicians is filtered through the emotional screens of patients and their families as ...Reference1. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001;134:1096-105. [PMID: 11412049] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: The Cancer Center of Chester County; West Chester, PA 19380 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPrognostic Disclosure to Patients with Cancer near the End of Life Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure Michael GuntherMaher Prognostic Disclosure Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure James R. Webster Jr. Prognostic Disclosure James R. Webster Jr. Prognostic Disclosure Elizabeth B. Lamont and Nicholas A. Christakis Prognostic Disclosure Michael GuntherMaher Metrics 3 September 2002Volume 137, Issue 5_Part_1Page: 368KeywordsBehaviorCancer chemotherapyCancer treatmentChemotherapyDisclosureEmotionsFearMotivationPalliative care ePublished: 3 September 2002 Issue Published: 3 September 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Relationship Between Pigment Deposits and Lesions in Normal and Centrilobular Emphysematous Lungs
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: R. D. NEWUMANN
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article BOOK REVIEWS Get access Cancer Imaging With Radiolabeled Antibodies: Cancer Treatment and Research . David M. Goldenberg , ed. Dordrecht , The Netherlands : Kluwer Academic Publishers , 1990 , 467 pp. $160. RONALD D. NEWUMANN RONALD D. NEWUMANN Nuclear Medicine Department, National Institutes of Health, Bldg 10, Rm IC450Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 7, 3 April 1991, Page 507, https://doi.org/10.1093/jnci/83.7.507 Published: 03 April 1991
Effect of intrauterine contraceptive devices on the endometrium
Authors: R. Israel
Journal: JAMA (1966)

The human uterine cavity is a space of variable size and configuration.<sup>1</sup>Intrauterine contraception, by its very nature, introduces a foreign body into this space, to the presence of which the uterus must accommodate. Any uterine-tissue reaction to the intrauterine device, if present, should be apparent in the endometrium, the lining of the uterine cavity in direct contact with the device. Intrauterine contraception has enjoyed a resurgence of popularity since 1959. During the past five years, uterine bacteriology<sup>2,3</sup>and cytology have been studied in association with the device. Other than superficial appraisal by the endometrial biopsy, uterine pathology has been given little reported attention.<sup>4</sup>Allen,<sup>5</sup>examining the histological findings from 18 uteri that had contained a stainless steel ring from six days to five months, noted no evidence of endometrial infection. More recently, Willson and his co-workers<sup>6</sup>reported on observations made of 292 endometrial specimens
HEAT AS AN INDUSTRIAL HEALTH HAZARD
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hyperbaric oxygen therapy of gas gangrene
Authors: H. J. Alvis
Journal: JAMA (1971)

<h3>To the Editor.—</h3> I am greatly consoled to learn my small role in prompting Harnes to look into the effects of "Pilfering the Prepuce." I yield to none in my admiration for his scientific attempt to decide whether he has been sexually deprived as a result of being circumcised. From some of the gratuitous comments I received following publication of "The Rape of the Phallus," several correspondents, who had suffered from balanitis or some other nasty disease of this region, maintained coitus was more satisfactory following circumcision, but an equal number complained that "they had been robbed." The latter usually were intact unmutilated males at the time they entered the service but by the completion of their tour of duty found themselves not only raped but sexually deprived—hardly "butchered to make a Roman holiday" but certainly "raped to keep an embryo plumber amused." In the same vein, I cannot but